利拉鲁肽联合德谷胰岛素治疗二甲双胍控制不佳的肥胖2型糖尿病患者的疗效分析

Efficacy analysis of combination therapy with liraglutide and insulin degludec in treatment of obese type 2 diabetes mellitus patients with poor glycemic control on metformin

目的分析利拉鲁肽联合德谷胰岛素治疗二甲双胍控制不佳的肥胖2型糖尿病患者的疗效。方法120例二甲双胍控制不佳的肥胖2型糖尿病患者,按照治疗方式不同分为对照组和观察组,每组60例。对照组接受利拉鲁肽治疗,观察组接受利拉鲁肽联合德谷胰岛素治疗。比较两组治疗效果及不良反应发生情况。结果观察组治疗总有效率为86.67%高于对照组的61.67%,差异有统计学意义(P<0.05)。观察组不良反应发生率为15.00%,低于对照组的35.00%,差异有统计学意义(P<0.05)。结论利拉鲁肽联合德谷胰岛素治疗二甲双胍控制不佳的肥胖2型糖尿病患者的疗效显著,且不良反应较少,值得临床推广。

Objective To analyze the efficacy of combination therapy with liraglutide and insulin degludec in treatment of obese type 2 diabetes mellitus patients with poor glycemic control on metformin.Methods A total of 120 obese type 2 diabetes mellitus patients with poor glycemic control on metformin were divided into control group and observation group according to different treatment methods,with 60 cases in each group.The control group was treated with liraglutide,and the observation group was treated with liraglutide and insulin degludec.The therapeutic effect and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 86.67%,which was higher than that of 61.67%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 15.00%,which was lower than that of 35.00%in the control group,and the difference was statistically significant(P<0.05).Conclusion Liraglutide combined with insulin degludec is effective in the treatment of obese type 2 diabetes mellitus patients with poor glycemic control on metformin,and has fewer adverse reactions,which is worthy of clinical promotion.